Ayako Tanaka

980 total citations
48 papers, 742 citations indexed

About

Ayako Tanaka is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Ayako Tanaka has authored 48 papers receiving a total of 742 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pulmonary and Respiratory Medicine, 22 papers in Oncology and 13 papers in Surgery. Recurrent topics in Ayako Tanaka's work include Lung Cancer Treatments and Mutations (20 papers), Lung Cancer Research Studies (10 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Ayako Tanaka is often cited by papers focused on Lung Cancer Treatments and Mutations (20 papers), Lung Cancer Research Studies (10 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Ayako Tanaka collaborates with scholars based in Japan, United States and United Kingdom. Ayako Tanaka's co-authors include Tomonori Hirashima, Norio Okamoto, Takayuki Shiroyama, Naoko Morishita, Hidekazu Suzuki, Motohiro Tamiya, Hisashi Takeuchi, Michio Tanaka, Hidekazu Suzuki and Yoshimi Noda and has published in prestigious journals such as Annals of Oncology, Journal of Biomedical Materials Research and World Journal of Gastroenterology.

In The Last Decade

Ayako Tanaka

45 papers receiving 735 citations

Peers

Ayako Tanaka
Yasuto Yoneshima Japan
Hironori Uruga Japan
Uzi Izhar Israel
Shuisheng Zhang China
Makoto Takahashi Japan
Nam Q. Bui United States
Vivek R. Sharma United States
A Bertrand France
Yuko Waseda Japan
Hideaki Yano Japan
Yasuto Yoneshima Japan
Ayako Tanaka
Citations per year, relative to Ayako Tanaka Ayako Tanaka (= 1×) peers Yasuto Yoneshima

Countries citing papers authored by Ayako Tanaka

Since Specialization
Citations

This map shows the geographic impact of Ayako Tanaka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ayako Tanaka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ayako Tanaka more than expected).

Fields of papers citing papers by Ayako Tanaka

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ayako Tanaka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ayako Tanaka. The network helps show where Ayako Tanaka may publish in the future.

Co-authorship network of co-authors of Ayako Tanaka

This figure shows the co-authorship network connecting the top 25 collaborators of Ayako Tanaka. A scholar is included among the top collaborators of Ayako Tanaka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ayako Tanaka. Ayako Tanaka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hirashima, Tomonori, Yoshimi Noda, Hidekazu Suzuki, et al.. (2021). Extracellular Water-to-total Body Water Ratio as an Objective Biomarker for Frailty in Lung Cancer Patients. Anticancer Research. 41(3). 1655–1662. 8 indexed citations
2.
Suzuki, Hidekazu, Takayuki Shiroyama, Ayako Tanaka, et al.. (2020). Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective study. Investigational New Drugs. 38(6). 1915–1920. 8 indexed citations
3.
Hirashima, Tomonori, Hidekazu Suzuki, Hiroko Yoshida, et al.. (2020). Significance of Pre-treatment Interferon-gamma Release in Patients With Non-small-cell Lung Cancer Receiving Immune Checkpoint Inhibitors. Anticancer Research. 40(12). 6971–6978. 4 indexed citations
4.
Suzuki, Hidekazu, Hiroko Yoshida, Yoshimi Noda, et al.. (2020). Significance of Quantitative Interferon-gamma Levels in Non-small-cell Lung Cancer Patients' Response to Immune Checkpoint Inhibitors. Anticancer Research. 40(5). 2787–2793. 17 indexed citations
5.
Hirashima, Tomonori, Hidekazu Suzuki, Hiroko Yoshida, et al.. (2019). The Levels of Interferon-gamma Release as a Biomarker for Non-small-cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. Anticancer Research. 39(11). 6231–6240. 35 indexed citations
6.
Suzuki, Hidekazu, Yuki Hara, Ayako Tanaka, et al.. (2019). Re-challenge chemotherapy in patients with sensitive relapse small-cell lung cancer and interstitial lung disease. Journal of Thoracic Disease. 11(2). 514–520.
7.
Masuhiro, Kentaro, Takayuki Shiroyama, Hidekazu Suzuki, et al.. (2018). Impact of Pleural Effusion on Outcomes of Patients Receiving Osimertinib for NSCLC HarboringEGFRT790M. Anticancer Research. 38(6). 3567–3571. 11 indexed citations
8.
Shiroyama, Takayuki, Hidekazu Suzuki, Motohiro Tamiya, et al.. (2018). Clinical Characteristics of Liver Metastasis in Nivolumab-treated Patients with Non-small Cell Lung Cancer. Anticancer Research. 38(8). 4723–4729. 43 indexed citations
9.
Tamiya, Motohiro, Hidekazu Suzuki, Takayuki Shiroyama, et al.. (2018). Clinical predictors of bevacizumab-associated intestinal perforation in non-small cell lung cancer. Investigational New Drugs. 36(4). 696–701. 8 indexed citations
10.
Hirashima, Tomonori, Yoshitaka Tamura, Shoji Hashimoto, et al.. (2018). Efficacy and safety of concurrent anti-Cancer and anti-tuberculosis chemotherapy in Cancer patients with active Mycobacterium tuberculosis: a retrospective study. BMC Cancer. 18(1). 975–975. 20 indexed citations
11.
12.
Shiroyama, Takayuki, Motohiro Tamiya, Ayako Tanaka, et al.. (2017). Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma. Respiratory Medicine Case Reports. 23. 68–70. 19 indexed citations
13.
Kanda, Shintaro, Hideaki Shiraishi, Ayako Tanaka, et al.. (2016). Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. Annals of Oncology. 27(12). 2242–2250. 85 indexed citations
14.
Shiroyama, Takayuki, Manabu Hayama, Ayako Tanaka, et al.. (2016). Successful retreatment with osimertinib after osimertinib-induced acute pulmonary embolism in a patient with lung adenocarcinoma: A case report. Respiratory Medicine Case Reports. 20. 25–27. 4 indexed citations
15.
Mizugaki, Hidenori, Yutaka Fujiwara, Noboru Yamamoto, et al.. (2014). Adjuvant Chemotherapy in Patients with Completely Resected Small Cell Lung Cancer: A Retrospective Analysis of 26 Consecutive Cases. Japanese Journal of Clinical Oncology. 44(9). 835–840.
16.
Tanaka, Ayako, Makoto Ohori, Yu Cheng, et al.. (2013). External Validation of Preoperative Nomograms Predicting Biochemical Recurrence after Radical Prostatectomy. Japanese Journal of Clinical Oncology. 43(12). 1255–1260. 5 indexed citations
17.
Gondo, Tatsuo, Makoto Ohori, Ayako Tanaka, et al.. (2011). The efficacy and safety of gemcitabine plus cisplatin regimen for patients with advanced urothelial carcinoma after failure of M-VAC regimen. International Journal of Clinical Oncology. 16(4). 345–351. 8 indexed citations
18.
Tanaka, Ayako, Tôru Nakamura, Takashi Koike, et al.. (2008). The Kii Bifurcation Current and Cold Eddy in Kii Channel. Oceanography in Japan. 17(3). 193–204.
19.
Sano, Soichi, Keiko Yamagami, Ayako Tanaka, et al.. (2008). A unique case of collagenous colitis presenting as protein-losing enteropathy successfully treated with prednisolone. World Journal of Gastroenterology. 14(39). 6083–6083. 8 indexed citations
20.
Yamamoto, Akiko, et al.. (1999). Generic tendency of metal salt cytotoxicity for six cell lines. Journal of Biomedical Materials Research. 47(3). 396–403. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yasuto Yoneshima Breakdown of academic impact, for papers by Hironori Uruga Breakdown of academic impact, for papers by Uzi Izhar Breakdown of academic impact, for papers by Shuisheng Zhang Breakdown of academic impact, for papers by Makoto Takahashi Breakdown of academic impact, for papers by Nam Q. Bui Breakdown of academic impact, for papers by Vivek R. Sharma Breakdown of academic impact, for papers by A Bertrand Breakdown of academic impact, for papers by Yuko Waseda Breakdown of academic impact, for papers by Hideaki Yano
Rankless by CCL
2026